Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Chief Research Officer | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,745 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 39,000 · Balance 154,745 F1: Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 194,395 |
Reported balance
After 2026-09-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Acquired 39,650 · Balance 194,395 |
| Common StockSEC Table I · non-derivative | Direct | 130,488 |
Reported balance
After 2026-09-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-15 · Sale · Disposed 63,907 · Balance 130,488 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 101,467 |
Reported balance
After 2026-09-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-15 · Sale · Disposed 29,021 · Balance 101,467 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 98,467 |
Reported balance
After 2026-09-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-15 · Sale · Disposed 3,000 · Balance 98,467 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5: The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided |
| Common StockSEC Table I · non-derivative | Direct | 98,197 |
Reported balance
After 2026-09-15 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-09-15 · Sale · Disposed 270 · Balance 98,197 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| Common StockSEC Table I · non-derivative | Direct | 98,547 |
Reported balance
After 2026-09-16 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2026-09-16 · Exercise / conversion · Acquired 350 · Balance 98,547 |
| Common StockSEC Table I · non-derivative | Direct | 153,547 |
Reported balance
After 2026-09-16 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2026-09-16 · Exercise / conversion · Acquired 55,000 · Balance 153,547 |
| Common StockSEC Table I · non-derivative | Direct | 211,047 |
Reported balance
After 2026-09-16 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2026-09-16 · Exercise / conversion · Acquired 57,500 · Balance 211,047 |
| Common StockSEC Table I · non-derivative | Direct | 145,943 |
Reported balance
After 2026-09-16 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2026-09-16 · Sale · Disposed 65,104 · Balance 145,943 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F6: The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 98,197 |
Reported balance
After 2026-09-16 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2026-09-16 · Sale · Disposed 47,746 · Balance 98,197 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F7: The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2028-05-10 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-15 · Exercise / conversion · Disposed 39,000 · Balance 0 F8: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 · Expires 2029-05-09 | Direct | 350 |
Reported balance
After 2026-09-15 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-15 · Exercise / conversion · Disposed 39,650 · Balance 350 F8: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.96 · Expires 2029-05-09 | Direct | 0 |
Reported balance
After 2026-09-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-16 · Exercise / conversion · Disposed 350 · Balance 0 F8: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.46 · Expires 2030-01-31 | Direct | 0 |
Reported balance
After 2026-09-16 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-16 · Exercise / conversion · Disposed 55,000 · Balance 0 F8: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.88 · Expires 2031-01-21 | Direct | 0 |
Reported balance
After 2026-09-16 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-09-16 · Exercise / conversion · Disposed 57,500 · Balance 0 F8: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3: The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided
F6: The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7: The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2019 Filed May 11, 2019 01:41 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029176 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,810 Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 00:58 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,250 | $21.52 | $26,900.00 |
DisclosureSEC source: 0001209191-19-011822 · doc4.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,810 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 15, 2019 Filed Feb 21, 2019 00:58 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,250 | $21.44 | $26,800.00 |
DisclosureSEC source: 0001209191-19-011822 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,060 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · balance_after: Includes 303 shares of the Issuer acquired by the reporting person on November 30, 2018 pursuant to an employee stock purchase program. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:49 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 992 | $21.50 | $21,328.00 |
DisclosureSEC source: 0001209191-19-009926 · doc4.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,007 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:49 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 993 | $21.38 | $21,230.34 |
DisclosureSEC source: 0001209191-19-009926 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,999 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 312 | $24.83 | $7,745.87 |
DisclosureSEC source: 0001209191-18-059065 · doc4.xml · nonDerivative · entry 4 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,992 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 to $24.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,188 | $24.25 | $53,054.62 |
DisclosureSEC source: 0001209191-18-059065 · doc4.xml · nonDerivative · entry 3 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,304 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.74 to $24.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 300 | $24.57 | $7,371.00 |
DisclosureSEC source: 0001209191-18-059065 · doc4.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,492 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:17 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,200 | $23.62 | $51,958.06 |
DisclosureSEC source: 0001209191-18-059065 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,792 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $23.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 09, 2018 Filed Nov 15, 2018 01:45 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058651 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,992 F1 · kind: On February 13, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner. F2 · balance_after: Includes 336 shares of the Issuer's common stock acquired by the reporting person on May 31, 2018 pursuant to an employee stock purchase program. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030059 · doc4.xml · derivative · entry 3 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 10, 2022 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 39,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030059 · doc4.xml · derivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| May 10, 2018 Filed May 14, 2018 23:35 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030059 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,656 Read SEC document |
| February 14, 2018 Filed Feb 17, 2018 00:39 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,034 | $21.50 | $22,232.03 |
DisclosureSEC source: 0001209191-18-011083 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,156 F1 · kind: Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU pursuant to a previous sell to cover election. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 01:40 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 1,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009401 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,190 F1 · balance_after: Includes 205 ordinary shares of the Issuer acquired by the reporting person on November 30, 2017 pursuant to an employee stock purchase program. Read SEC document |
| February 13, 2017 Filed Feb 16, 2017 01:03 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $20.61 | $0.00 |
DisclosureSEC source: 0001209191-17-011305 · doc4.xml · derivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-02-12 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option shall vest and become exercisable on the first anniversary of the date of grant, and the remaining shares shall vest and become exercisable in twelve equal quarterly installments thereafter. Read SEC document |
| February 13, 2017 Filed Feb 16, 2017 01:03 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011305 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.